TVTX
TRAVERE THERAPEUTICS INC
Latest close $62.76 as of Aug 5, 2026
Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred
from changes in reported shares when available; it is not a list of individual trades or exact execution prices.
Form 13F rows are quarter-end holding context only and do not establish an exact entry date.
Free access includes current parsed ownership filings, reported share changes, and ownership-percentage changes.
Significance scoring, disclosure-speed analysis, confirmation/divergence signals, and signal alerts require Investor or Pro.
Compare plans.
Beneficial ownership filing history
Showing 3 of 5 parsed filing(s) · 2 older require more history access| Holder | Observed / filed | Reported change | Shares | Ownership | Observation | Filing | Latest |
|---|---|---|---|---|---|---|---|
| Vanguard Capital Management CIK0002100119 | Mar 31, 2026 observed Apr 30, 2026 filed · 30d Initial Schedule 13G | Initial Schedule 13G | 4.7M | 12.00% | $29.71 | $42.12 | $62.76 |
| Vanguard Group CIK0000102909 | Mar 13, 2026 observed Mar 27, 2026 filed · 14d Schedule 13G amendment | Earliest Schedule 13G amendment found | 11 | 12.00% | $27.80 | $27.25 | $62.76 |
| State Street CIK0000093751 | Dec 31, 2025 observed Feb 9, 2026 filed · 40d Initial Schedule 13G | Initial Schedule 13G | 4.8M | 12.00% | $38.21 | $30.07 | $62.76 |